Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers developing new arsenal in war against cancer

16.12.2002


In the battle against cancer, Virginia Tech researchers have developed a potential warhead to better kill cancer cells, a new missile to deliver the warhead more efficiently to the diseased areas, and a new detonation device once the warhead is in place.



In a cross-disciplinary effort, the researchers, using photodynamic therapy (PDT), have obtained results in three different areas that, used together, have the possibility of providing more efficient, less invasive, and more specific treatments for cancer and other diseases such as age-related macular-degeneration.

A long-term concept has held that one should be able to use light-activated compounds to kill diseased cells, said Karen Brewer, associate professor of chemistry. The researchers have developed new tri-metallic supra-molecules that can be positioned in exact parts of cancer cells and excited by a therapeutic wavelength at which light propagates efficiently through tissue. Only when the light hits the supra-molecules do they become toxic to the cancer cells.


The advantages are many. The non-surgical process avoids the debilitating side effects of normal chemotherapy. The system enables the scientists to place the supra-molecules at specific locations in cells and to deliver light activating the cancer-killing molecules directly at that spot in a strength that does not harm other tissue. "This allows much lower dosages of light to be effective, so we can use agents that are more aggressive and not get the side effects of chemotherapy," Brewer said.

Researchers Shawn Swavey and Alvin Holder, along with students Lee Williams and Nathan Toft, working in the Brewer laboratory, developed the new mixed-metal supra-molecular complexes (medicines) that Brewer and Brenda Winkel, professor of biology, have proven are capable of photo-cleaving DNA, a normal therapeutic target in cells. The complexes are novel molecules whose chemistry allows the researchers to append them to other units.

At present, physicians use a chemical that is exposed to light and activates oxygen in photodynamic therapy. In tumor cells, oxygen is depleted rapidly, so those treatments can run out of oxygen and not kill the entire tumor, which can return. Brewer’s new systems don’t need oxygen, and the researchers can change the wavelength of light used. "We can fine tune the compound for light-absorbing characteristics," Brewer said. "By using a lower energy, we can better penetrate the body."

Brian Storrie, professor of biochemistry, and research scientist Maria Teresa Tarrago-Trani of biochemistry have developed the "rocket" with which to deliver the cancer-killing agents to particular organelles, or parts, in the cancer cells. "We have used a polypeptide that binds to a cell surface receptor, and that molecule is over-expressed for certain cancers. We can deliver photosynthesizers to the cancer," Storrie said.

The delivery vehicle is a B-fragment of a class of toxins known as shiga toxins. The A fragment is toxic, but the B fragment is a non-toxic delivery system. Storrie developed a way to use the B fragment to deliver the photo-dynamic agents developed by Brewer into the cells. This enables the researchers to target certain kinds of cancer cells that have receptors for the B fragment and deliver the agent to the exact spot in the cell so the supra-molecule can attack that part. This allows for the destruction of many parts in the cancerous cells.

Ken Meissner, senior research scientist with the Optical Science and Engineering Research (OSER) Center at Virginia Tech is developing the "detonation device" for the supra-molecules, which are nontoxic until hit by light. His specialty is the delivery of light to the correct tissues and to the supra-molecules positioned to kill the cells. Meissner develops better ways to get the light to the tumor and to understand how light passes through tissue

Together, the three-part attack opens up huge new areas for fighting cancer. "We can attach the delivery vehicles, change the light we need, change the biological target in the cells, and design a molecule that reacts with that part," Brewer said. In other words, Brewer can develop different molecules for different areas of the cells, Storrie can develop ways to get those molecules to the right places in the cells, and Meissner can develop methods to deliver the light needed to begin the killing of cancer cells. Or, Meissner can develop a new light-delivery system to work in a certain area, and then Brewer can develop a molecule that will kill tumor cells when excited with this light, and Storrie can get the molecule there.

The possibilities are greatly expanded by the variety of supra-molecules and the interactive work of these researchers. This exciting work is in the early stages, but the researchers hope it will someday be the basis for important strides in the treatment of cancer and other diseases.

The research is being done within the OSER Photodynamics Mini-center, a joint effort between the Carilion Biomedical Institute and Virginia Tech. Research groups collaborating under the mini-center include researchers Brewer, Storrie, Meissner, and Winkel, and Yannis Besieris and Brad Davis of electrical and computer engineering, Sun Young Kim of biochemistry, and Ed Wojcik of biology, all of Virginia Tech


Researcher contact information:
Karen Brewer 540-231-6579, kbrewer@vt.edu,
Brian Storrie 540-231-6434, storrie@vt.edu,
Ken Meissner 540-231-2512, cmeissne@vt.edu

PR CONTACT: Sally Harris 540-231-6759 slharris@vt.edu


Karen Brewer | EurekAlert!
Further information:
http://www.chem.vt.edu/chem-dept/brewer/brewer.html
http://www.biochem.vt.edu/faculty/storrie.html

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>